戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              HIPEC comprised mitomycin C 15 mg/m(2) and cisplatin 75
2                                              HIPEC did not increase AEs.
3                                              HIPEC through the closed abdomen technique employed cisp
4                                              HIPEC was performed using a one-time administration of o
5                                              HIPEC with carboplatin was well tolerated but did not re
6                                              HIPEC with cisplatin (CDDP) 75 mg/m(2) for 60 minutes at
7                                              HIPEC-cisplatin and HIPEC-paclitaxel, administered durin
8  disruptions associated with intra-abdominal HIPEC is critical to ensure effective anesthetic managem
9 ational guidelines include the option to add HIPEC to interval CRS for patients with stage III ovaria
10         Our findings implicate that adjuvant HIPEC should still be performed in trial setting only.
11 l rate between patients assigned to adjuvant HIPEC followed by systemic chemotherapy or only adjuvant
12 are at risk for poor clinical outcomes after HIPEC + CS, including greater risk of 30-day morbidity a
13 d recurrence-free and overall survival after HIPEC in patients with ovarian cancer who are ineligible
14 to either adjuvant systemic chemotherapy and HIPEC (n = 100) or adjuvant systemic chemotherapy alone
15                          HIPEC-cisplatin and HIPEC-paclitaxel, administered during iCRS.
16 uvant chemotherapy in the setting of CRS and HIPEC for PMs.
17 reating these patients with interval CRS and HIPEC in countries with comparable health care systems.
18  trial data, treatment with interval CRS and HIPEC in patients with stage III ovarian cancer was acco
19 the Netherlands, indicating interval CRS and HIPEC is cost effective for this patient population.
20                              Of 2637 CRS and HIPEC operations, 1102 patients (female, 64.4%; median a
21                                      CRS and HIPEC to treat PSM has a steep learning curve requiring
22                                      CRS and HIPEC to treat PSM is a complex procedure with a signifi
23 to be associated with survival after CRS and HIPEC, but no definitive analysis has been made to valid
24  variables on overall survival after CRS and HIPEC.
25  variables on overall survival after CRS and HIPEC.
26 m colorectal cancer are treated with CRS and HIPEC.
27 on to a curative procedure combining CRS and HIPEC.
28 ry to ensure surgical proficiency in CRS and HIPEC.
29 ere enrolled to undergo laparoscopic CRS and HIPEC.
30 ents who had cytoreductive surgery (CRS) and HIPEC in a single institution between 1994 and 2018.
31 en patients had a complete cytoreduction and HIPEC, 10 (77%) laparoscopically and 3 (23%) were conver
32 dvanced ovarian cancer who received iCRS and HIPEC.
33 lity and safety of cytoreductive surgery and HIPEC via the laparoscopic route in selected patients wi
34 jectives included postoperative toxicity and HIPEC pharmacokinetics.
35 ciated with comparable oncologic outcomes as HIPEC-cisplatin, suggesting that it could be a viable al
36 dy of patients with advanced ovarian cancer, HIPEC-paclitaxel was associated with comparable oncologi
37 operatively randomly assigned to carboplatin HIPEC (800 mg/m(2) for 90 minutes) or no HIPEC, followed
38 be followed by intraperitoneal chemotherapy (HIPEC or EPIC procedures).
39 d hyperthermic intraperitoneal chemotherapy (HIPEC) achieve good results in selected patients with pe
40 d hyperthermic intraperitoneal chemotherapy (HIPEC) across time and according to hospital-volume.
41   Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery have been shown to bene
42 d hyperthermic intraperitoneal chemotherapy (HIPEC) are being widely used in the treatment of patient
43 d hyperthermic intraperitoneal chemotherapy (HIPEC) are still being debated.
44 d hyperthermic intraperitoneal chemotherapy (HIPEC) consolidated through an international registry st
45 h hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal cancers can be associated with sig
46 h hyperthermic intraperitoneal chemotherapy (HIPEC) has become an important therapeutic option for se
47 c hyperthermic intraperitoneal chemotherapy (HIPEC) in these patients.
48   Hyperthermic intraperitoneal chemotherapy (HIPEC) is a single intraoperative procedure that deliver
49 g hyperthermic intraperitoneal chemotherapy (HIPEC) is common.
50 f hyperthermic intraperitoneal chemotherapy (HIPEC) is to eradicate microscopic residual tumor after
51 t hyperthermic intraperitoneal chemotherapy (HIPEC) might prevent peritoneal metastases after curativ
52 t hyperthermic intraperitoneal chemotherapy (HIPEC) regimens could provide crucial insights to improv
53 f hyperthermic intraperitoneal chemotherapy (HIPEC) remains controversial.
54 f hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery (CRS) improved
55 e hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin for recurrent ovarian cancer dur
56 n hyperthermic intraperitoneal chemotherapy (HIPEC)-like treated 3D colorectal tumor mimics.
57 h hyperthermic intraperitoneal chemotherapy (HIPEC).
58 d hyperthermic intraperitoneal chemotherapy (HIPEC).
59 h hyperthermic intraperitoneal chemotherapy (HIPEC).
60 d hyperthermic intraperitoneal chemotherapy (HIPEC).
61 d heated intraperitoneal chemotherapy (CRS & HIPEC) is the current standard of care in selected patie
62  and associated with not responding to CRS & HIPEC.
63 g patient selection for treatment with CRS & HIPEC and in future research into novel and personalised
64 tify those suitable for treatment with CRS & HIPEC and to identify targets for existing repurposed or
65 hort of patients with CPM treated with CRS & HIPEC was recruited and divided according to prognosis.
66 h CPM not responding to treatment with CRS & HIPEC, to identify those suitable for treatment with CRS
67 election of patients as candidates for CRS + HIPEC; however, the rPCI value cannot be considered in i
68                                          CRS-HIPEC improved overall survival (OS) in both crude and I
69 ere we aimed to compare outcomes between CRS-HIPEC versus CRS alone (CRSa) among patients with PMs fr
70 perthermic intraperitoneal chemotherapy (CRS-HIPEC) alone for resectable colorectal peritoneal metast
71  the proportions of macroscopic complete CRS-HIPEC (33 of 37 [89%] vs 36 of 42 [86%] patients; risk r
72      Proportions of macroscopic complete CRS-HIPEC and Clavien-Dindo grade 3 or higher postoperative
73                      Compared with CRSa, CRS-HIPEC improved OS and recurrence-free survival, without
74                   Upon IPTW analysis, in CRS-HIPEC and CRSa groups, median OS was 18.8 versus 12.1 mo
75 ion to perioperative systemic therapy or CRS-HIPEC alone.
76           When complete CRS is possible, CRS-HIPEC may be considered a valuable therapy for strictly
77 neal cancer index remained higher in the CRS-HIPEC group (6 v 2; P = .003).
78         Of these patients, 180 underwent CRS-HIPEC and 97 CRSa.
79                                          CRS/HIPEC is an effective therapeutic strategy commonly used
80                          A total of 7476 CRS/HIPEC were analyzed.
81            A cut-off value of the annual CRS/HIPEC caseload affecting the 90-day POM was calculated u
82                               In France, CRS/HIPEC is a safe procedure with an acceptable 90-day POM
83                         The threshold of CRS/HIPEC number per center per year above which the 90-day
84 itigate morbidity in patients undergoing CRS/HIPEC.
85 erative morbidity in patients undergoing CRS/HIPEC.
86 ion and morbidity in patients undergoing CRS/HIPEC.
87                All patients treated with CRS/HIPEC between 2009 and 2018 in France were identified th
88  cells and nontransformed human enterocytes (HIPEC) were subjected to 10% average cyclic strain at 10
89 ion of DDC improves the efficacy of existing HIPEC protocols in a safe way and may open the door to a
90          Ninety-eight patients scheduled for HIPEC + CS completed the Center for Epidemiologic Studie
91 [11.01] years) were included (325 [38.4%] in HIPEC-cisplatin group; 521 [61.6%] in HIPEC-paclitaxel g
92 4%] in HIPEC-cisplatin group; 521 [61.6%] in HIPEC-paclitaxel group), and 199 patients in each group
93 PM organoids cisplatin is superior to MMC in HIPEC.
94 pen the door to a more effective, multimodal HIPEC.
95 tin HIPEC (800 mg/m(2) for 90 minutes) or no HIPEC, followed by five or six cycles of postoperative I
96                              The addition of HIPEC to complete or nearly complete primary SCS did not
97 s randomized clinical trial, the addition of HIPEC to complete surgical resection for locally advance
98 ed the cost effectiveness of the addition of HIPEC to interval CRS in patients with ovarian cancer.
99  colorectal cancer did not show a benefit of HIPEC when added to perioperative chemotherapy.
100 inment of the perioperative complications of HIPEC.
101 nsity score was used to assess the effect of HIPEC and account for confounding factors.
102                                The effect of HIPEC for patients with ovarian cancer undergoing primar
103 mechanism of action, safety, and efficacy of HIPEC in the treatment of peritoneal metastases from epi
104                     Anesthetic management of HIPEC is further impacted by these developments.
105 Available data investigating the outcomes of HIPEC are mostly limited to single-center studies.
106  investigating the postoperative outcomes of HIPEC.
107 t selection, timing, and optimal regimens of HIPEC to improve the effectiveness of this specialized t
108                    A retrospective review of HIPEC cases performed for primary and metastatic periton
109                                  The role of HIPEC in colorectal cancer is less well defined.
110       This study does not support the use of HIPEC with carboplatin during secondary cytoreductive su
111 ity Improvement Program hospitals performing HIPEC have acceptable rates of morbidity and mortality.
112 organoids (PTOs) in elucidating personalized HIPEC responses to bypass rarity of disease in generatin
113 emotherapy and CRS alone (CRS-A) or CRS plus HIPEC (CRS + H).
114 2.11 to 3.28 QALYs) in the interval CRS plus HIPEC group.
115 78,766 to euro 93,935) for interval CRS plus HIPEC.
116 y assigned 1:1 to receive cytoreduction plus HIPEC with mitomycin C (30 mg/m2 over 60 minutes; invest
117 t random assignment, 82 patients to SCS plus HIPEC (experimental arm) and 85 to SCS alone (control ar
118 75.9% (95% CI, 66.5 to 85.3) in the SCS plus HIPEC group.
119                           Open high-pressure HIPEC with oxaliplatin is feasible in the pig.
120            Of 98 patients, 49 (50%) received HIPEC.
121 eal chemotherapy with cytoreductive surgery (HIPEC + CS).
122 tion to the ambitious, long-lasting surgery, HIPEC causes significant fluid, blood and protein losses
123                                          The HIPEC regimen was selected based on the standard clinica
124  The median progression-free survival in the HIPEC and standard arms were 12.3 and 15.7 months, respe
125 00) were without progression or death in the HIPEC arm and 12 (24.5%; 1-sided 90% CI, 16.5 to 100) in
126 tion was performed in 37% of patients in the HIPEC arm compared with 65% in the standard (P = .008).
127 e gross resection was achieved in 82% of the HIPEC patients and 94% of the standard-arm patients.
128        Among these 398 matched patients, the HIPEC-paclitaxel group had similar DFS and OS compared w
129 oup had similar DFS and OS compared with the HIPEC-cisplatin group.
130 y gathered data of adult patients undergoing HIPEC at our health system between November 2013 and Apr
131 KI with high accuracy in patients undergoing HIPEC in our institution.
132 nsive care management of patients undergoing HIPEC.
133 tion [CCR], 2 or 3; P < .001), and not using HIPEC (P = .030) as independent predictors for a poorer
134 treated by 131 procedures combining CRS with HIPEC.
135                            Cytoreducion with HIPEC is an effective but potentially morbid treatment o
136 tients undergoing cytoreductive surgery with HIPEC.
137 up that underwent cytoreductive surgery with HIPEC.
138 s suspended in ECM-hydrogel and treated with HIPEC regimen parameters.

 
Page Top